Adenoma Prevention with Celecoxib (APC) trial
Jump to navigation
Jump to search
Introduction
2035 patients colorectal adenomas
celecoxib 200 mg or 400 mg BID vs placebo
Results:
- after 3 years, risk of non fatal myocardial infarction, stroke or death from cardiovascular causes greater in celecoxib groups 2.2% (200 mg) & 3.0% (400 mg) vs 0.9% (placebo)
References
- ↑ Journal Watch 25(6):45, 2005 Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/15713944 <Internet> http://content.nejm.org/cgi/reprint/NEJMoa050405.pdf